United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

On February2, 2017, the Board of Directors (the
Board)
of United Therapeutics Corporation (the Company) adopted
the Companys Fifth Amended and Restated By-Laws (the
Amended
By-laws). The Amended By-laws include the following
amendments:

Provide greater specificity regarding the information
requirements for any nominee for election or re-election as a
director of the Company regardless of method of nomination,
including (i)a written representation and agreement by the
nominee representing that such nominee (a)consents to being named
in the Companys proxy materials as a nominee and currently
intends to serve the full term of the position, (b)is not and
will not become a party to any arrangement as to how the nominee
will act or vote on an issue that has not been disclosed to the
Company or that could limit or interfere with the nominees
ability to comply, if elected, with his or her fiduciary duties
as a director, (c)is not and will not become a party to an
arrangement with respect to any direct or indirect compensation
in connection with service or action as a director or nominee
that has not been disclosed to the Company, and (d)if elected,
will comply with all of the Companys corporate governance,
conflict of interest, confidentiality, stock ownership and
trading policies and guidelines and other policies and guidelines
applicable to directors; (ii)a completed and signed questionnaire
required of the Companys directors; and (iii)such other
information as the Company may reasonably request.
[Section2.15]

Allow any two authorized officers to sign stock certificates in
conformity with Section158 of the General Corporation Law of the
State of Delaware. [Section6.1]

The Amended By-laws also include certain technical and conforming
amendments. The Amended By-laws became effective upon adoption by
the Board. The foregoing summary is qualified in its entirety by
the full text of the Amended By-laws, a copy of which is attached
hereto as Exhibit3.1 and incorporated herein by reference.

Item 9.01 Exhibits.

(d) Exhibits

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.

United Therapeutics Corporation (NASDAQ:UTHR) Recent Trading Information

United Therapeutics Corporation (NASDAQ:UTHR) closed its last trading session up +1.07 at 165.10 with 547,608 shares trading hands.